ALLIANCES (Pfizer) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 11,068	$ 10,540	$ 10,129	$ 10,781	$ 7,945	$ 6,007	$ 6,273	$ 5,920	$ 42,518		$ 26,145		$ 22,561
Cost of products sold									11,773	[1]	8,078	[1]	6,467
Other (Income)/Expense, Net - Collaborative Arrangement									(2,314)		938		(854)
Receivables	8,501				7,685				8,501		7,685
Accounts payable	2,713				2,445				2,713		2,445
Eliquis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									9,168		7,929		6,438
Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									9,979		10,541		9,006
Cost of products sold									4,485		4,169		3,439
Other (Income)/Expense, Net - Collaborative Arrangement									(74)		(60)		(67)
Receivables	343				347				343		347
Accounts payable	1,093				1,026				1,093		1,026
Deferred income	366				431				366		431
Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									9,168		7,929		6,438
Cost of products sold									4,331		3,745		3,078
Other (Income)/Expense, Net - Collaborative Arrangement									(55)		(55)		(55)
Receivables	253				247				253		247
Accounts payable	1,024				922				1,024		922
Deferred income	$ 300				$ 355				$ 300		355
Collaborative Arrangement [Member] | Pfizer [Member] | Eliquis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum percentage of reimbursement for development costs from alliance partner	50.00%								50.00%
Maximum percentage of reimbursement for development costs from alliance partner	60.00%								60.00%
Total upfront, milestone and other licensing payments received to date	$ 884								$ 884
Net product sales [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									41,321		25,174		21,581
Net product sales [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									9,364		9,944		8,359
Net product sales [Member] | Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									8,942		7,711		6,329
Collaborative Arrangement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									615		597		647
Collaborative Arrangement [Member] | Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									$ 226		$ 218		$ 109

[1] Excludes amortization of acquired intangible assets.